Geron Corporation investor relations material

Geron Corporation focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company has a portfolio of drugs in clinical trials that address a number of blood cancers, including acute myeloid leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). In AML, it develops GRN163L/GRN163L-AQ, which is an oral small molecule Bruton's tyrosine kinase inhibitor (BTKi) initially planned for regulatory filing in the U.S., Canada, and Europe in the third quarter 2014 to treat patients with previously treated AML with FLT3 -ITD or V617F mutation and in the fourth quarter 2014 to treat patients with relapsed or refractory pediatric AML with FLT3-ITD or V617F mutation; GRN703/GRN703-AQ, an oral inhibitor of both Btk and IgE Fcepsilon receptors (FCER1A), which is being developed to treat patients with eosinophil-related diseases, including allergic asthma and atopic dermatitis.